Schedule 13D ownership disclosure

Nautilus Biotechnology, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 63909J108

Event date: 2026-10-05

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Perceptive Advisors LLCReported CIK 0001224962

    Shares: 4,944,512.00 · Class: 3.9%

  • Joseph EdelmanReported CIK 0001164426

    Shares: 4,944,512.00 · Class: 3.9%

  • Perceptive Life Sciences Master Fund, Ltd.Reported CIK 0001249675

    Shares: 4,778,652.00 · Class: 3.8%

  • C2 Life Sciences LLCReported CIK 0001890152

    Shares: 165,860 · Class: 0.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-445289
Form type
SCHEDULE 13D/A
Filer
Nautilus Biotechnology, Inc.
CIK
CIK 1808805
Filed
Nov 03, 2026
Reporting period
Oct 05, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub